title: The complex relation between bisphosphonate adherence and fracture reduction.
abstract: BACKGROUND
  Real-world adherence to bisphosphonate therapy is poor. Consistent data support a relation between medication adherence and fracture reduction, but relatively little attention has been paid to the effect of the method used to measure adherence on this relation or on the relation between adherence and specific fracture types.
  
  
  OBJECTIVE
  Our objective was to assess the relation between bisphosphonate adherence and the risk of hip, vertebral, distal forearm, and any fracture using different measures of adherence.
  
  
  METHODS
  We conducted a cohort study using administrative claims data. Adherence was assessed in sequential 60-d periods. In models incorporating time-varying measures of adherence, the adjusted relation between adherence and fracture was examined using several methods for calculating the proportion of days covered (PDC).
  
  
  METHODS
  Patients included community-dwelling elderly enrolled in a Pennsylvania pharmaceutical assistance program and Medicare initiating an oral bisphosphonate for osteoporosis.
  
  
  METHODS
  Risk of hip, vertebral, distal forearm, and any osteoporotic fracture was assessed.
  
  
  RESULTS
  Fractures occurred at a rate of 43 per 1000 person-years among the 19,987 patients meeting study eligibility criteria. There was an inverse relation between adherence and fracture rate for all adherence measures and fracture types, excluding distal forearm fractures. High (80-100%) cumulative PDC was associated with a 22% reduction in overall fracture rate, a 23% reduction in hip fracture rate, and 26% reduction in vertebral fracture rate.
  
  
  CONCLUSIONS
  We found a consistent relation between adherence with osteoporosis treatment and fracture reduction, regardless of method for measuring PDC. The similarity in results across adherence measures is likely due to the high correlation between them.
authors.affiliation: Divisions of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA. arpatrick@partners.org
authors.forename: Amanda R
authors.initials: AR
authors.lastname: Patrick
authors.forename: M Alan
authors.initials: MA
authors.lastname: Brookhart
authors.forename: Elena
authors.initials: E
authors.lastname: Losina
authors.forename: John T
authors.initials: JT
authors.lastname: Schousboe
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Cadarette
authors.forename: Helen
authors.initials: H
authors.lastname: Mogun
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Solomon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D015331:Cohort Studies; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology* / Q000517:prevention & control; D006306:Health Surveys; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D010414:Pennsylvania; D015995:Prevalence; D012044:Regression Analysis; D012306:Risk; D012307:Risk Factors; D016903:Drug Monitoring
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
references.citation: J Bone Miner Res. 2008 Sep;23(9):1435-41
references.pmid: 18442318
references.citation: Mayo Clin Proc. 2007 Dec;82(12):1493-501
references.pmid: 18053457
references.citation: Osteoporos Int. 2009 Nov;20(11):1969-72
references.pmid: 19184268
references.citation: Health Serv Res. 2003 Aug;38(4):1103-20
references.pmid: 12968819
references.citation: Mayo Clin Proc. 2006 Aug;81(8):1013-22
references.pmid: 16901023
references.citation: BMC Musculoskelet Disord. 2007 Sep 26;8:97
references.pmid: 17897451
references.citation: Osteoporos Int. 2007 Mar;18(3):271-7
references.pmid: 17021945
references.citation: Endocr Rev. 2002 Aug;23(4):570-8
references.pmid: 12202472
references.citation: Epidemiology. 1994 Sep;5(5):541-4
references.pmid: 7986870
references.citation: J Clin Epidemiol. 1992 Jul;45(7):703-14
references.pmid: 1619449
references.citation: JAMA. 1998 Dec 23-30;280(24):2077-82
references.pmid: 9875874
references.citation: Bone. 2007 Nov;41(5):882-7
references.pmid: 17707710
references.citation: Am J Epidemiol. 2007 Aug 1;166(3):348-54
references.pmid: 17504779
references.citation: J Clin Epidemiol. 1992 Jun;45(6):613-9
references.pmid: 1607900
references.citation: Br J Clin Pharmacol. 2008 Jul;66(1):117-27
references.pmid: 18460036
references.citation: Osteoporos Int. 2011 Mar;22(3):943-54
references.pmid: 20532481
references.citation: Osteoporos Int. 2008 Apr;19(4):511-7
references.pmid: 17874028
references.citation: Med Care. 2009 Jan;47(1):69-72
references.pmid: 19106733
references.citation: Bone. 2006 Jun;38(6):922-8
references.pmid: 16330270
references.citation: Health Econ. 2001 Oct;10(7):601-15
references.pmid: 11747044
references.citation: Value Health. 2008 Jan-Feb;11(1):44-7
references.pmid: 18237359
references.citation: J Bone Miner Res. 2007 Mar;22(3):465-75
references.pmid: 17144789
references.citation: Osteoporos Int. 2009 Jan;20(1):23-34
references.pmid: 18521650